ATRIAL FIBRILLATION MARKET ANALYSIS

Atrial Fibrillation Market, by Procedure (Pharmacological (Anti-arrhythmic and Anti-coagulant), Non-Pharmacological (Catheter Ablation Procedures, Maze surgery and Electric Cardioversion), by Technology (Radiofrequency, Laser, Cryotherapy and Others), by End User Hospitals, Speciality, Clinics and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Oct 2022
Code : CMI205
Pages :140
Formats :
Excel and PDF
Industry : Medical Devices

Market News

Global Atrial Fibrillation Market: Key Developments

On August 24, 2022, physIQ, which uses wearable biosensor data to generate personalized, clinically valid, actionable insights announced a strategic collaboration with InCarda Therapeutics, Inc., and a privately-held, clinical-stage biopharmaceutical company developed inhaled therapies for cardiovascular diseases. This collaboration will accelerate Phase III Study in patients with atrial fibrillation.

On August 30, 2022, Medtronic plc, which is a U.S. medical device company, announced that it has completed the acquisition of Affera, Inc., a medical technology company . This acquisition expands the Medtronic plc company's cardiac ablation portfolio to include its first-ever cardiac mapping and navigation platform that encompasses a differentiated, fully integrated diagnostic, focal pulsed field and radiofrequency ablation solution.